Annovis Bio Signs GMP Manufacturing Agreement to Support Planned Late- Stage StudiesNewsfile Corp • 03/11/21
Annovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve InjuryNewsfile Corp • 03/10/21
Annovis Bio to Present at the H.C. Wainwright Global Life Sciences ConferenceNewsfile Corp • 03/09/21
Annovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain InsultsNewsfile Corp • 02/04/21
Annovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice StudyNewsfile Corp • 02/02/21
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money ReportGlobeNewsWire • 12/17/20
Annovis Bio Showcases its Unique Approach to Alzheimer's at the New York Academy of SciencesGlobeNewsWire • 12/15/20
Annovis Bio to Present at the New York Academy of Sciences' Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual ConferenceGlobeNewsWire • 12/03/20
Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer's and Parkinson's DiseasesGlobeNewsWire • 11/12/20
Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer's Disease after COVID-Related DelayGlobeNewsWire • 10/29/20
Annovis Bio CEO Participates in Roundtable Discussion at the Financial Times' Outstanding Directors Exchange and Panel Discussion at the Angel Venture FairGlobeNewsWire • 10/20/20
Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s DiseaseGlobeNewsWire • 09/29/20
Annovis Bio Begins Treatment of First Patients in its Phase 2a Alzheimer’s and Parkinson’s TrialGlobeNewsWire • 09/01/20
Annovis Bio Actively Recruiting Patients for its Phase 2a Trials in Alzheimer’s and Parkinson’s DiseasesGlobeNewsWire • 08/20/20